Answers are grounded in this paper and cite their sources.
There was no difference in BCVA between faricimab and anti-VEGF monotherapy in nAMD, DME, and RVO. While faricimab offered superior improvement in CSFT at the final follow-up for DME and RVO eyes, this effect was not seen in nAMD eyes. Future studies are needed to establish the long-term safety and efficacy of faricimab for retinal vascular disease.
No takes yet. Share an insight, caveat, or question.
Nichani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: